Kraft Heinz
KHC
$24.34
+1.84%
The Kraft Heinz Company is one of North America's largest packaged food and beverage manufacturers, producing condiments, sauces, cheese, meats, frozen meals, and beverages under iconic brands including Kraft, Heinz, Oscar Mayer, Velveeta, and Philadelphia, with roughly 85% of sales through retail and a growing foodservice presence across more than 190 countries. The company is a mature, brand-owning incumbent in the Consumer Defensive sector rather than a growth disruptor, and its competitive identity rests on shelf-stable brand equity and scale distribution, though it has ceded ground to private-label and nimbler challengers. The current investor narrative centers on a turnaround that is still in its early stages, with the core business shrinking, a recent multi-billion-dollar impairment-driven loss, and persistent questions about whether management can stabilize volumes and margins. Sentiment is further colored by speculation over Berkshire Hathaway's long-held stake and whether new leadership will exit the position, while bulls point to a high dividend yield and deep value multiples as compensation for patience.…
KHC
Kraft Heinz
$24.34
Related headlines
Investment Opinion: Should I buy KHC Today?
Rating: Hold. The core thesis is that KHC is a deep-value, high-yield defensive name whose cash generation ($3.816 billion FCF) and 6.63% dividend yield compensate for a shrinking core business, but the analyst consensus Hold (mean 3.05) and average target of $24.69—essentially at the $24.80 price—signal no near-term catalyst for re-rating. The stock is fairly valued after its recent rally, not undervalued enough to justify new money without evidence of volume stabilization.
Supporting evidence: (1) valuation is cheap on cash—6.42x PCF and ~7.5x P/FCF versus a market multiple well above that; (2) the 11.94x forward PE compares favorably to the mid-to-high teens of higher-growth food peers; (3) the 6.63% dividend yield is covered by FCF, with $475 million paid in Q2 2026 while repaying $1.829 billion of debt; (4) the balance sheet is manageable at 0.509 debt-to-equity and a 1.154 current ratio. However, revenue growth is -1.42% YoY and GAAP margins are negative (-87.19% net margin) due to impairments, so the value case depends on normalization toward the $2.24 consensus FY EPS.
Biggest risks: recurring impairments ($5.46 billion in Q2 2026) could force further write-downs; the Berkshire overhang could pressure shares if the stake is sold; and a dividend reset would remove the main support for the equity. This Hold would upgrade to Buy if organic revenue growth turns positive or if the stock pulls back toward the $21-$22 support zone (near the 52-week low of $21.035) while FCF holds above $3.5 billion. It would downgrade to Sell if revenue declines accelerate beyond -3% or if gross margin falls below 32%. Verdict: fairly valued relative to its own history and at a discount to peers, but the discount is justified until volumes stabilize.
Sign up to view all
KHC 12-Month Price Forecast
KHC is a fairly valued defensive value stock with a covered high yield and a solid balance sheet, but the shrinking core business (-1.42% revenue growth) and recurring impairments ($5.46 billion in Q2 2026) cap upside. The analyst consensus target of $24.69 sits at the current price, and the wide $19-$41 range reflects genuine uncertainty about the turnaround. The base case (55% probability) sees the stock range-bound between $23 and $27 as declines moderate, while the bull case (25%) requires volume stabilization and multiple expansion toward $32-$41. I would upgrade to bullish if organic revenue growth turns positive or if the stock pulls back toward $21 with FCF intact; I would downgrade to bearish if revenue declines accelerate beyond -3% or if the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kraft Heinz's 12-month outlook, with a consensus price target around $24.69 and implied upside of +1.5% versus the current price.
Average Target
$24.69
0 analysts
Implied Upside
+1.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$19 - $41
Analyst target range
Coverage is solid with 18 analysts, but the consensus recommendation is a lukewarm Hold (recommendation mean of 3.05 on a scale where higher is more bearish), and the average target price of $24.69 sits essentially at the current $24.80 price, implying roughly -0.4% downside to consensus. That flat target-to-price relationship signals that the Street views the stock as fairly valued after its recent rally, with little conviction in either direction. The consensus leans neutral-to-cautious rather than bullish, consistent with the shrinking core business and early-stage turnaround narrative.
The full target range of $19.00 to $41.00 is extremely wide, spanning about -23% downside to +65% upside from the current price, which signals high uncertainty and divergent views on the turnaround. The $41 high target likely assumes successful volume stabilization, margin recovery, and multiple expansion toward peer levels, while the $19 low target prices in continued share loss, further impairments, or a dividend reset. Institutional ratings show a stable, mostly neutral pattern with no recent upgrades: RBC Capital reiterated Outperform on 2026-09-24, while TD Cowen, Evercore ISI, Barclays, UBS, and Piper Sandler all maintained Hold/Neutral/In Line stances through August-September 2026, indicating analysts are waiting for tangible evidence of a turnaround before turning constructive.
Bulls vs Bears: KHC Investment Factors
The bear case currently has stronger evidence: revenue is declining (-1.42% YoY), impairments are recurring ($5.46 billion in Q2 2026 after $7.824 billion in Q2 2025), and the analyst consensus target of $24.69 implies no upside from $24.80. The bull case rests on cash-flow valuation (6.42x PCF), a covered 6.63% dividend yield, and a solid balance sheet (D/E 0.509), but these are compensation for patience rather than catalysts for near-term appreciation. The single most important tension is whether volumes stabilize: if the core Condiments, Sauces, and Spreads franchise ($2.897 billion, the dominant segment) can return to growth, the deep-value multiple could re-rate toward peer levels; if declines persist, the stock remains a value trap. The recent 15% rally from $21.84 to $25.09 shows sentiment can shift quickly, but without fundamental confirmation it looks like mean reversion rather than a durable trend change.
Bullish
- Deep value on cash flow: At $24.80, KHC trades at 6.42x price-to-cash-flow and roughly 7.5x price-to-free-cash-flow (implied by $3.816 billion FCF against a $28.6 billion market cap), well below the market multiple. The 11.94x forward PE and 1.15x PS are near the bottom of the company's own historical range (PS was 4.3x-4.5x as recently as Q1-Q2 2026).
- High dividend yield with cash coverage: The 6.63% dividend yield is covered by $3.816 billion in trailing free cash flow, and the company returned $475 million in dividends in Q2 2026 while still repaying $1.829 billion of debt. The negative payout ratio (-32.47%) is an artifact of the impairment-driven GAAP loss, not a cash-flow problem.
- Balance sheet remains solid: Debt-to-equity of 0.509 and a current ratio of 1.154 indicate manageable leverage for a packaged-food issuer. Quarterly operating cash flow of $1.082 billion and FCF of $893 million show the core business still generates substantial cash despite the headline loss.
- Analyst target range skews upside: The $41 high target implies +65% upside from $24.80, and the $19 low target implies -23% downside, a favorable risk/reward skew if the turnaround gains traction. RBC Capital reiterated Outperform on 2026-09-24, showing some conviction remains.
Bearish
- Core revenue is shrinking: Q2 2026 revenue of $6.262 billion fell 1.42% year over year, following $6.047 billion in Q1 2026 and $6.354 billion in Q4 2025. The flat-to-declining trajectory reflects volume pressure in mature categories, and top-line recovery is the missing catalyst for a durable re-rating.
- Recurring impairments signal brand erosion: Q2 2026 recorded a $5.46 billion net loss and -$4.60 EPS driven by a non-cash impairment, following a -$7.824 billion impairment in Q2 2025. The pattern of repeated write-downs indicates carrying values still exceed realistic growth expectations for the brands.
- Analyst consensus offers no upside: The average target price of $24.69 sits essentially at the current $24.80 price, implying -0.4% downside, and the recommendation mean of 3.05 is a lukewarm Hold. Most covering analysts (TD Cowen, Evercore ISI, Barclays, UBS, Piper Sandler) maintain Hold/Neutral stances, waiting for tangible turnaround evidence.
- Valuation discount may be structural: The PS ratio has collapsed from 6.0x-7.0x in 2022-2023 to 1.15x today, and PB has fallen from roughly 0.90x in 2023 to 0.69x. This persistent de-rating reflects structural deterioration in brand relevance and growth rather than a temporary dislocation.
KHC Technical Analysis
KHC is in a range-bound consolidation with a modestly negative longer-term tilt, having posted a 1-year price change of -2.40% against a current price of $24.80. That price sits at roughly 53% of the 52-week range between the $21.035 low and $28.09 high, placing the stock in the middle of its band rather than at an extreme, which signals indecision and a lack of directional conviction rather than either momentum overextension or a falling-knife setup. The 6-month gain of 13.04% shows the stock has recovered meaningfully off its lows even as the 1-year figure remains slightly negative, consistent with a base-building pattern.
Short-term momentum has turned constructive and is diverging positively from the longer-term trend: the 1-month change of +4.25% and 3-month change of -3.39% bracket a choppy summer, but the recent thrust from the October 5 close of $21.84 to the October 22 close of $25.09 represents a sharp ~15% rally in under three weeks. Relative strength confirms the shift, with 1-month relative strength of +5.27 versus SPY even as 1-year relative strength lags at -15.53, suggesting the stock is in a mean-reversion rebound phase rather than a durable new uptrend. Volume of roughly 9.86 million shares and a short ratio of 4.27 indicate moderate short interest that could fuel further squeezes on strength, though the -1.16% pullback on the latest session to $24.80 shows the rally is meeting resistance.
Key technical levels are well defined: support rests at the 52-week low of $21.035, with the recent $21.84 October trough acting as a secondary floor, while resistance sits at the $28.09 52-week high and the $27.62 late-July peak as an intermediate ceiling. A breakout above $28.09 would signal a genuine trend change and likely invite momentum buyers, whereas a breakdown below $21.035 would confirm the longer-term downtrend and open deeper downside. Volatility is unusually low for an equity, with a beta of just 0.111 implying roughly 89% less volatility than the market, and a max drawdown of -20.93% over the period; this low-beta profile supports defensive position sizing but also means the stock will likely lag in strong risk-on rallies.
Beta
0.11
0.11x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$21-$28
Price range past year
Annual Return
-1.0%
Cumulative gain past year
| Period | KHC Return | S&P 500 |
|---|---|---|
| 1m | +7.1% | -0.9% |
| 3m | -5.8% | +1.2% |
| 6m | +8.2% | +4.9% |
| 1y | -1.0% | +11.2% |
| ytd | -0.2% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KHC Fundamental Analysis
Revenue is stagnating to slightly declining: the most recent quarter (ended 2026-06-27) posted $6.262 billion, down 1.42% year over year, following $6.047 billion in Q1 2026, $6.354 billion in Q4 2025, and $6.237 billion in Q3 2025, a flat-to-shrinking trajectory consistent with volume pressure in mature categories. Segment data shows Condiments, Sauces, and Spreads as the dominant contributor at $2.897 billion, followed by Ambient Meals and Sides at $679 million and Refreshment Beverages at $584 million, while smaller lines like Coffee ($225 million) and Other Category ($58 million) are marginal; the concentration in condiments means overall growth hinges on that franchise offsetting declines elsewhere. The implication for the investment case is that top-line recovery, not cost-cutting alone, is the missing catalyst for a durable re-rating.
Profitability is severely distorted by a large non-cash impairment: the latest quarter reported a net loss of $5.46 billion and EPS of -$4.60, driving a net margin of -87.19% and operating margin of -102.70%, with EBITDA of -$6.011 billion. Excluding that charge, the underlying business remains solidly profitable, as evidenced by Q1 2026 net income of $798 million (13.20% net margin) and Q4 2025 net income of $651 million (10.25% net margin), while gross margin has held in a narrow 32.4%-34.4% band across recent quarters (33.31% currently). The pattern of recurring impairment charges in Q2 2025 (-$7.824 billion) and Q2 2026 (-$5.46 billion) points to ongoing brand write-downs rather than operational collapse, but it also signals that carrying values still exceed realistic growth expectations.
Balance sheet and cash generation remain the strongest part of the story: free cash flow TTM is $3.816 billion, quarterly FCF was $893 million in Q2 2026 with operating cash flow of $1.082 billion, and the debt-to-equity ratio of 0.509 is manageable for a packaged-food issuer. Liquidity is adequate with a current ratio of 1.154, and the company returned cash via $475 million in dividends in the quarter while repaying $1.829 billion of debt; however, ROE of -14.03% and ROA of 3.63% reflect the impairment drag, and the dividend payout ratio of -32.47% is negative only because of the accounting loss. The key takeaway is that KHC funds itself internally and covers its dividend from cash flow, but the 6.63% dividend yield is high precisely because the equity has de-rated, leaving less margin for error if FCF softens.
Quarterly Revenue
$6.3B
2026-06
Revenue YoY Growth
-1.4%
YoY Comparison
Gross Margin
32.4%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KHC Overvalued?
Because trailing net income is negative (EPS of -$0.204 and a trailing PE of -4.89), the PE ratio is not meaningful, so the primary metric selected is the forward PE of 11.94x, supported by the price-to-sales ratio of 1.15x and EV/Sales of 1.84x. The gap between the unusable trailing PE and the 11.94x forward multiple implies the market expects earnings to normalize sharply toward the consensus FY EPS estimate of $2.24, but the negative EV/EBITDA of -13.38x confirms that GAAP EBITDA is still distorted by impairments. On a cash basis, the PCF ratio of 6.42x and price-to-free-cash-flow near 7.5x (implied by $3.816 billion FCF against a $28.6 billion market cap) suggest the stock is genuinely cheap on cash generation.
Against the packaged foods peer set, KHC screens at a discount on most measures: a PS ratio of 1.15x and PB of 0.69x are well below the roughly 2x-3x sales and 2x-4x book multiples typical of branded staples peers, and the 11.94x forward PE compares favorably to the mid-to-high teens multiples often commanded by higher-growth food companies. The discount is partly justified by the -1.42% revenue decline, negative GAAP margins, and repeated impairments, but the 6.63% dividend yield and 0.69x book value suggest the market is pricing in substantial skepticism about the turnaround. In short, this is a classic value trap-versus-value opportunity setup where the premium/discount debate hinges entirely on whether volumes stabilize.
Historically, KHC's own valuation band has compressed dramatically: the PS ratio was 6.0x-7.0x in 2022-2023 and 4.3x-4.5x as recently as Q1-Q2 2026 on the historical ratios data, versus 1.15x today, while the PB ratio has fallen from roughly 0.90x in 2023 to 0.69x now. The trailing PE history is noisy (8.2x in Q1 2026, 10.97x in Q4 2025, 12.5x in Q3 2025) but consistently in the single-to-low-double digits, confirming the stock has traded at a persistent discount to the broader market for years. Current levels sit near the bottom of the company's own historical range, which either signals a genuine value opportunity if the turnaround gains traction or reflects structural deterioration in brand relevance and growth.
PE
-4.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the shrinking top line and recurring impairments. Q2 2026 revenue of $6.262 billion declined 1.42% year over year, and the $5.46 billion net loss (-$4.60 EPS) followed a $7.824 billion impairment in Q2 2025, showing that brand carrying values remain inflated relative to realistic growth. The 6.63% dividend yield, while covered by $3.816 billion in trailing FCF, leaves less margin for error if cash flow softens; the negative payout ratio (-32.47%) is an accounting artifact but highlights earnings volatility. Concentration in Condiments, Sauces, and Spreads ($2.897 billion of segment revenue) means overall growth hinges on that franchise offsetting declines elsewhere.
Market and competitive risks include valuation compression and private-label pressure. The stock trades at 11.94x forward PE and 1.15x PS, already a discount to branded staples peers at 2x-3x sales, but the discount could widen if the turnaround stalls; the PS ratio has fallen from 6.0x-7.0x in 2022-2023 to 1.15x today. Beta of 0.111 means low market correlation, but the 1-year relative strength of -15.53 versus SPY shows the stock has lagged badly, and sector rotation away from defensives would compound the underperformance. Speculation over Berkshire Hathaway's stake (recent news suggests the new CEO may exit) adds a potential supply overhang, while competitors like PepsiCo (recent Q3 revenue/EPS beat despite North America weakness) and private-label challengers continue to pressure volumes.
Worst-case scenario: continued volume declines force another multi-billion-dollar impairment, management cuts or resets the dividend, and Berkshire exits its stake, triggering a re-rating toward the analyst low target of $19.00. From $24.80, that implies roughly -23% downside, and a break below the 52-week low of $21.035 (about -15% from current) would confirm the longer-term downtrend and open deeper losses. The max drawdown over the period was -20.93%, so a -23% to -25% adverse move is within historical experience. The key trigger to monitor is whether gross margin, currently 33.31%, holds above 32% while volumes stabilize; a breach would signal that pricing power is eroding faster than cost cuts can offset.
FAQ
The most severe risk is financial: recurring impairments ($5.46 billion in Q2 2026 after $7.824 billion in Q2 2025) signal that brand values may still be overstated, and a dividend reset would remove the main support for the equity. Competitive risk is high, with private-label and nimbler challengers pressuring volumes in mature categories, evidenced by the -1.42% revenue decline. Macro risk is moderate given the low beta of 0.111, but sector rotation away from defensives and the 1-year relative strength of -15.53 versus SPY show the stock can lag badly. Company-specific risk includes the Berkshire Hathaway overhang—speculation that the new CEO may exit the stake—which could create selling pressure. Ranked by severity: financial/impairment risk first, competitive/volume risk second, Berkshire overhang third, and macro/rotation fourth.
The 12-month forecast has three scenarios: a base case (55% probability) of $23-$27, assuming revenue declines moderate to -1% to -2% and the dividend is maintained; a bull case (25% probability) of $32-$41, requiring volume stabilization, gross margin expansion above 34%, and multiple re-rating toward peers; and a bear case (20% probability) of $19-$21, driven by accelerating declines, another impairment, or a dividend cut. The base case is most likely because the analyst average target of $24.69 already sits at the current price and the consensus is a Hold. The key assumption behind the base case is that free cash flow remains above $3.5 billion, covering the 6.63% dividend and preventing a reset.
KHC appears undervalued on cash-based metrics but fairly valued on earnings: the 6.42x PCF and ~7.5x P/FCF are well below market averages, and the 1.15x PS and 0.69x PB are at deep discounts to branded staples peers at 2x-3x sales and 2x-4x book. However, the 11.94x forward PE already reflects the $2.24 consensus EPS, and the analyst average target of $24.69 implies the stock is fully priced at $24.80. The PS ratio has collapsed from 6.0x-7.0x in 2022-2023 to 1.15x today, so the market is pricing in substantial skepticism about brand relevance and growth. The valuation implies the market expects continued low-single-digit declines and no near-term re-rating; a return to growth would justify a higher multiple.
From a risk/reward perspective, KHC offers a covered 6.63% dividend yield and trades at 6.42x cash flow, with the analyst high target of $41 implying +65% upside and the low target of $19 implying -23% downside. However, the consensus target of $24.69 is essentially at the current $24.80 price, and the recommendation mean of 3.05 is a Hold, suggesting limited near-term upside. The biggest downside risk is a dividend reset or another large impairment, which could push the stock toward $19-$21. It is a good buy primarily for income-focused, patient investors who can tolerate a multi-year turnaround and want defensive exposure with a low beta of 0.111; it is less suitable for growth-oriented investors seeking capital appreciation.
KHC is better suited for long-term holding than short-term trading. Its beta of 0.111 means low volatility and limited short-term trading opportunities, while the 6.63% dividend yield and 6.42x cash-flow valuation reward patience. The stock is in a base-building phase—6-month gain of 13.04% but 1-year change of -2.40%—and the turnaround is in early stages, so earnings visibility is low and a quick re-rating is unlikely. A suggested minimum holding period is 2-3 years to allow the turnaround to play out and to collect dividends, with a stop-loss consideration below the 52-week low of $21.035. Short-term traders might find the recent 15% rally from $21.84 to $25.09 attractive, but the -1.16% pullback on the latest session shows resistance near $25-$26.